CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope
J. Clin. Invest. Ania Skowera, et al.
doi:10.1172/JCI35449 [Go to this article.]

Problems with a PDF?